今日（3.6），港股、A股生物医药板块全线大涨！同类0.15%最低档费率的恒生生物科技ETF汇添富（513280）放量收涨3.85%，连续第二日大举反攻，全 天成交额超1.2亿元！资金面上，恒生生物科技ETF汇添富（513280）近60日净流入超1300万元。 消息面上，在今年重要工作报告中，生物医药被明确列入国家层面的"新兴支柱产业"，与集成电路、航空航天、低空经济等产业并列。这是重要工作报告中 首次以支柱产业的定位提出发展生物医药产业，释放出推动产业加速升级的重要政策信号。 | 序号 | 代码 | 名称 | 估算权重 | 涨跌幅 | 成交额 ▼ | | --- | --- | --- | --- | --- | --- | | 1 | 2269 | 药明生物 | 12.47% | 0.45% | 12.43亿 | | 2 | 1530 | 三生制药 | 3.94% | 9.52% | 9.36亿 | | 3 | 1801 | 信达生物 | 9.23% | 6.25% | 8.75亿 | | 4 | 6618 | 京东健康 | 2.73% | 1.18% | 8.53亿 | | 5 | 9926 | 康方生 ...

Core Points - The company is holding its annual general meeting to discuss various proposals, including financial reports and governance changes [1][3][19] - The meeting will take place on June 26, 2025, at 14:00 in Yantai, China, with both on-site and online voting options available [4][5][6] Meeting Procedures - Attendees must register and verify their identity to participate in the meeting [1][2] - Shareholders have the right to speak, ask questions, and vote on proposals, but must adhere to the meeting's agenda and time limits [2][3] - The meeting will be conducted in an orderly manner, with the chairman having the authority to manage discussions and responses to questions [2][3][4] Agenda Items - The meeting will review and vote on several key proposals, including: - The 2024 annual board report [8][10] - The 2024 annual supervisory report [10] - The 2024 financial settlement report, which has been audited and approved [11] - The 2024 annual report and its summary [12] - A proposal for profit distribution, indicating no distribution for 2024 [13] - The reappointment of accounting firms for 2025 [13] - Confirmation of director and supervisor remuneration for 2024 [14][18] - A proposal for general authorization to issue new shares [15][16] - Changes to the company's registered capital and governance structure, including the abolition of the supervisory board [17][21] - Amendments to the company's articles of association and meeting rules [19][20][22] Financial Performance - The company reported significant sales growth, particularly from its products, with a revenue of 1.699 billion yuan from one of its drugs [24] - The company is focused on maintaining high R&D investment while reducing net losses compared to previous years [24]